Biochemical Modulators of Tight Junctions (TJs): Occludin, Claudin-2 and Zonulin As Biomarkers of Intestinal Barrier Leakage in the Diagnosis and Assessment of Inflammatory Bowel Disease Progression

Overview

Journal Molecules

Publisher MDPI

Specialty Biology

Date 2024 Oct 16

PMID 39407507

Authors

Aleksandra Gorecka

Agnieszka Jura-Poltorak

Ewa M Kozma

Anna Szeremeta

Krystyna Olczyk

Katarzyna Komosinska-Vassev

Affiliations

Soon will be listed here.

Abstract

Background: Considering the increasing worldwide prevalence of inflammatory bowel disease (IBD), the early diagnosis of this disease is extremely important. However, non-invasive diagnostic methods remain limited, while invasive techniques are the most commonly used in daily practice. Therefore, there is a serious need to find new non-invasive biomarkers of IBD.

Methods: The serum profiles of occludin, claudin-2, and zonulin were assessed in IBD patients using the ELISA method. The levels of the analyzed biomarkers were measured before and after a year of anti-inflammatory treatment, which was a tumor necrosis factor α (TNF-α) inhibitor (adalimumab) in patients with ulcerative colitis (UC) and conventional therapy in patients with Crohn's disease (CD).

Results: In IBD patients, the serum level of occludin ( < 0.001) decreased compared to healthy individuals, while the level of claudin-2 ( < 0.001) increased. Additionally, zonulin ( < 0.01) concentration increased in CD patients compared to the control group. The highest diagnostic ability was presented by occludin measurements with the area under the curve (AUC) of 0.959 (95% CI 0.907-1) in UC and 0.948 (95% CI 0.879-1) in CD. Claudin-2 also demonstrated very good ability in diagnosing UC and CD with AUC values of 0.864 (95% CI 0.776-0.952) and 0.896 (95% CI 0.792-0.999), respectively. The ability of zonulin to diagnose CD was estimated as good with an AUC of 0.74 (95% CI 0.598-0.881). Moreover, a significant correlation was identified between C-reactive protein (CRP), claudin-2 (r = -0.37; < 0.05), and zonulin (r = -0.44; < 0.05) in UC patients. Treatment with adalimumab improved the level of occludin, claudin-2, and zonulin in UC patients, while anti-inflammatory conventional therapy decreased the concentration of zonulin in CD.

Conclusions: Occludin and claudin-2 measurements present significant utility in diagnosing both UC and CD, while zonulin assessments may be useful in CD diagnosis. Additionally, claudin-2 and zonulin measurements may be helpful in evaluating the intensity of the inflammatory process. Anti-TNF-α treatment improved the value of occludin, claudin-2, and zonulin, indicating its beneficial effect on the integrity of tight junctions in UC.

References

Wang W, Uzzau S, Goldblum S, Fasano A . Human zonulin, a potential modulator of intestinal tight junctions. J Cell Sci. 2000; 113 Pt 24:4435-40. DOI: 10.1242/jcs.113.24.4435. View

Kushlinskii N, Gershtein E, Zybina N, Tsarapaev P, Salyanova E, Korotkova E . Blood Serum Zonulin in Colorectal Cancer, Autoimmune Bowel Diseases, and Irritable Bowel Syndrome. Bull Exp Biol Med. 2022; 173(3):376-379. DOI: 10.1007/s10517-022-05552-w. View

Weber C, Nalle S, Tretiakova M, Rubin D, Turner J . Claudin-1 and claudin-2 expression is elevated in inflammatory bowel disease and may contribute to early neoplastic transformation. Lab Invest. 2008; 88(10):1110-20. PMC: 2586671. DOI: 10.1038/labinvest.2008.78. View

Yu Y, Rodriguez J . Clinical presentation of Crohn's, ulcerative colitis, and indeterminate colitis: Symptoms, extraintestinal manifestations, and disease phenotypes. Semin Pediatr Surg. 2017; 26(6):349-355. DOI: 10.1053/j.sempedsurg.2017.10.003. View

Soubieres A, Poullis A . Emerging role of novel biomarkers in the diagnosis of inflammatory bowel disease. World J Gastrointest Pharmacol Ther. 2016; 7(1):41-50. PMC: 4734953. DOI: 10.4292/wjgpt.v7.i1.41. View

Kuo W, Odenwald M, Turner J, Zuo L . Tight junction proteins occludin and ZO-1 as regulators of epithelial proliferation and survival. Ann N Y Acad Sci. 2022; 1514(1):21-33. PMC: 9427709. DOI: 10.1111/nyas.14798. View

Billmeier U, Dieterich W, Neurath M, Atreya R . Molecular mechanism of action of anti-tumor necrosis factor antibodies in inflammatory bowel diseases. World J Gastroenterol. 2016; 22(42):9300-9313. PMC: 5107694. DOI: 10.3748/wjg.v22.i42.9300. View

Suzuki T, Yoshinaga N, Tanabe S . Interleukin-6 (IL-6) regulates claudin-2 expression and tight junction permeability in intestinal epithelium. J Biol Chem. 2011; 286(36):31263-71. PMC: 3173073. DOI: 10.1074/jbc.M111.238147. View

Xu P, Elamin E, Elizalde M, Bours P, Pierik M, Masclee A . Modulation of Intestinal Epithelial Permeability by Plasma from Patients with Crohn's Disease in a Three-dimensional Cell Culture Model. Sci Rep. 2019; 9(1):2030. PMC: 6375954. DOI: 10.1038/s41598-018-38322-8. View

10.

Capaldo C . Claudin Barriers on the Brink: How Conflicting Tissue and Cellular Priorities Drive IBD Pathogenesis. Int J Mol Sci. 2023; 24(10). PMC: 10218714. DOI: 10.3390/ijms24108562. View

11.

Dahlen R, Strid H, Lundgren A, Isaksson S, Raghavan S, Magnusson M . Infliximab inhibits activation and effector functions of peripheral blood T cells in vitro from patients with clinically active ulcerative colitis. Scand J Immunol. 2013; 78(3):275-84. DOI: 10.1111/sji.12081. View

12.

El Asmar R, Panigrahi P, Bamford P, Berti I, Not T, Coppa G . Host-dependent zonulin secretion causes the impairment of the small intestine barrier function after bacterial exposure. Gastroenterology. 2002; 123(5):1607-15. DOI: 10.1053/gast.2002.36578. View

13.

Prasad S, Mingrino R, Kaukinen K, Hayes K, Powell R, Macdonald T . Inflammatory processes have differential effects on claudins 2, 3 and 4 in colonic epithelial cells. Lab Invest. 2005; 85(9):1139-62. DOI: 10.1038/labinvest.3700316. View

14.

Cummins P . Occludin: one protein, many forms. Mol Cell Biol. 2011; 32(2):242-50. PMC: 3255790. DOI: 10.1128/MCB.06029-11. View

15.

Souza R, Caetano M, Magalhaes H, Castelucci P . Study of tumor necrosis factor receptor in the inflammatory bowel disease. World J Gastroenterol. 2023; 29(18):2733-2746. PMC: 10237104. DOI: 10.3748/wjg.v29.i18.2733. View

16.

Guan Q . A Comprehensive Review and Update on the Pathogenesis of Inflammatory Bowel Disease. J Immunol Res. 2019; 2019:7247238. PMC: 6914932. DOI: 10.1155/2019/7247238. View

17.

Kucharzik T, Walsh S, Chen J, Parkos C, Nusrat A . Neutrophil transmigration in inflammatory bowel disease is associated with differential expression of epithelial intercellular junction proteins. Am J Pathol. 2001; 159(6):2001-9. PMC: 1850599. DOI: 10.1016/S0002-9440(10)63051-9. View

18.

Veres-Szekely A, Szasz C, Pap D, Szebeni B, Bokrossy P, Vannay A . Zonulin as a Potential Therapeutic Target in Microbiota-Gut-Brain Axis Disorders: Encouraging Results and Emerging Questions. Int J Mol Sci. 2023; 24(8). PMC: 10139156. DOI: 10.3390/ijms24087548. View

19.

Piovezani Ramos G, Papadakis K . Mechanisms of Disease: Inflammatory Bowel Diseases. Mayo Clin Proc. 2019; 94(1):155-165. PMC: 6386158. DOI: 10.1016/j.mayocp.2018.09.013. View

20.

He W, Wang J, Sheng J, Zha J, Graham W, Turner J . Contributions of Myosin Light Chain Kinase to Regulation of Epithelial Paracellular Permeability and Mucosal Homeostasis. Int J Mol Sci. 2020; 21(3). PMC: 7037368. DOI: 10.3390/ijms21030993. View